{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:47:13Z","timestamp":1792784833551,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Pharos I&BT Co, Ltd"},{"name":"This work was supported by the Korea Health Industry Development Institute (KHIDI) grant funded by the Ministry of Health and Welfare, Republic of Korea","id":[{"id":"https:\/\/ror.org\/00vxgjw72","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-026-03171-2","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:26:56Z","timestamp":1791826016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PHI-101: a novel FLT3 inhibitor with potent activity against the F691L gatekeeper resistance mutation"],"prefix":"10.1038","author":[{"given":"Marina","family":"Mitrou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao Ho","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi-Jun","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9450-9953","authenticated-orcid":false,"given":"Ky-Youb","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Hyeok","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0885-8568","authenticated-orcid":false,"given":"David","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Seale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hye","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taebo","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3410-7000","authenticated-orcid":false,"given":"Donald","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"3171_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401:2073\u201386.","journal-title":"Lancet"},{"key":"3171_CR2","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute Myeloid Leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100:860\u201391.","journal-title":"Am J Hematol"},{"key":"3171_CR3","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/sj.leu.2403099","volume":"17","author":"M Levis","year":"2003","unstructured":"Levis M, Small D. FLT3: it does matter in leukemia. Leukemia. 2003;17:1738\u201352.","journal-title":"Leukemia"},{"key":"3171_CR4","first-page":"1911","volume":"10","author":"M Nakao","year":"1996","unstructured":"Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911\u20138.","journal-title":"Leukemia"},{"key":"3171_CR5","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532\u201342.","journal-title":"Blood"},{"key":"3171_CR6","doi-asserted-by":"crossref","unstructured":"Small D. FLT3 mutations: biology and treatment. Hematol Am Soc Hematol Educ Program. 2006:178\u201384.","DOI":"10.1182\/asheducation-2006.1.178"},{"key":"3171_CR7","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","volume":"97","author":"Y Yamamoto","year":"2001","unstructured":"Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434\u20139.","journal-title":"Blood"},{"key":"3171_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3324\/haematol.2019.240754","volume":"106","author":"AJ Ambinder","year":"2021","unstructured":"Ambinder AJ, Levis M. Potential targeting of FLT3 acute myeloid leukemia. Haematologica. 2021;106:671\u201381.","journal-title":"Haematologica"},{"key":"3171_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nature11016","volume":"485","author":"CC Smith","year":"2012","unstructured":"Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485:260\u20133.","journal-title":"Nature"},{"key":"3171_CR10","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1158\/0008-5472.CAN-04-2148","volume":"64","author":"J Cools","year":"2004","unstructured":"Cools J, Mentens N, Furet P, Fabbro D, Clark JJ, Griffin JD, et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 2004;64:6385\u20139.","journal-title":"Cancer Res"},{"key":"3171_CR11","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1158\/2159-8290.CD-15-0060","volume":"5","author":"CC Smith","year":"2015","unstructured":"Smith CC, Zhang C, Lin KC, Lasater EA, Zhang Y, Massi E, et al. Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 \u201cGatekeeper\u201d F691L mutation with PLX3397. Cancer Discov. 2015;5:668\u201379.","journal-title":"Cancer Discov"},{"key":"3171_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1182\/bloodadvances.2019000919","volume":"4","author":"TC Tarver","year":"2020","unstructured":"Tarver TC, Hill JE, Rahmat L, Perl AE, Bahceci E, Mori K, et al. Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. Blood Adv. 2020;4:514\u201324.","journal-title":"Blood Adv"},{"key":"3171_CR13","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.3390\/cancers14174315","volume":"14","author":"D Capelli","year":"2022","unstructured":"Capelli D, Menotti D, Fiorentini A, Saraceni F, Olivieri A. Overcoming resistance: FLT3 inhibitors past, present, future and the challenge of cure. Cancers. 2022;14:4315.","journal-title":"Cancers"},{"key":"3171_CR14","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2024-207033","volume":"144","author":"Dong-Yeop Shin","year":"2024","unstructured":"Shin Dong-Yeop, Yoon Sung-Soo, Hong Junshik, Lee Je-Hwan, Jang Jun-Ho, Cheong June-won, et al. PHI-101, a novel FLT3 TKI, shows clinical efficacy in relapsed\/refractory FLT3-mutated AML. Blood. 2024;144:1495.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03171-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03171-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03171-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:26:57Z","timestamp":1791826017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03171-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":14,"alternative-id":["3171"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03171-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DS has served as a paid consultant to Pharos I&BT Co., Ltd. and currently serves on the Scientific Advisory Board. This arrangement has been reviewed by the Johns Hopkins University in accordance with its conflict of interest policies. GJS, KYN, KTK, and JHY are employed by Pharos iBio Co., Ltd. and have stock ownership in the company. S-HC and TS have patents and royalties associated with PHI-101.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}